ArticleJournal of renal injury prevention2017
Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy.
Article in Journal of renal injury prevention, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.Medicine · 2020Pooled it
- Cardiotoxicity of Targeted Therapies in Hematologic Malignancies: From Molecular Mechanisms to Clinical Management.Current treatment options in oncology · 2026Review
- Rituximab-Induced Acute Coronary Syndrome.Cureus · 2025Article
- Cardiac Involvement in Eosinophilic Granulomatosis with Polyangiitis.Current cardiology reports · 2025Review
- Article
- Differential Cardiotoxicity of Ibrutinib Versus Chemoimmunotherapy in Chronic Lymphocytic Leukemia: A Population-Based Study.Journal of clinical medicine · 2024Article
- Reversible Dilated Cardiomyopathy in a Male Patient With Rheumatoid Arthritis: A Case Report.Cureus · 2024Article
- Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy.Drugs · 2023Review
- Cardiac involvement and cardiovascular risk factors in pediatric primary systemic vasculitides.Clinical rheumatology · 2023Review
- Eosinophilic granulomatosis with polyangiitis - Advances in pathogenesis, diagnosis, and treatment.Frontiers in medicine · 2023Review
- Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma-a review and prospects for the future.Frontiers in cardiovascular medicine · 2023Review
- At the Heart of Eosinophilic Granulomatosis with Polyangiitis: into Cardiac and Vascular Involvement.Current rheumatology reports · 2022Review
- Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Cancer Chemotherapy-Induced Sinus Bradycardia: A Narrative Review of a Forgotten Adverse Effect of Cardiotoxicity.Drug safety · 2022Review
- Off-Label Uses of Rituximab in Dermatology.Current dermatology reports · 2022Review
- Takotsubo Syndrome (TTS) in Onco-Hematologic Patients: Retrospective Analysis and Focus on the Correlation or Not With Anticancer Drugs. Case Reports and Review of the Literature.Frontiers in oncology · 2022Article
- A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma.Cardio-oncology (London, England) · 2020Review
- Rituximab as a novel treatment for heart failure: evidence from a case series.European heart journal. Case reports · 2019Article
- Article
- Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study.Pediatric nephrology (Berlin, Germany) · 2019Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rituximab is an anti-CD20 monoclonal antibody frequently used for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), and anti-neutrophilic cytoplasmic antibody (ANCA)-associated vasculitis. In addition, rituximab has recently been increasingly used as an off-label treatment in a number of inflammatory and systemic autoimmune diseases. It is advised that rituximab infusion may cause infusion reactions and adverse cardiac effects including arrhythmia and angina, especially in patients with prior history of cardiovascular diseases. However, its detailed cardiotoxicity profile and effects on cardiac function were not well described. We report a 51-year-old man who developed non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. The patient experienced reduced cardiac functions within 48 hours after the initial infusion, which remained markedly reduced at 9-month follow-up. As the utility of rituximab expands, physicians must be aware of this serious cardiovascular adverse effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.